Robert D. Warren
Georgetown University Medical Center · 26 works · 1,222 citations · h-index 15
Top works
- The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast Cancer
- Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer
- Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
- Membrane transport of methotrexate in human lymphoblastoid cells.
- Abnormal Pulmonary Gallium Accumulation inP. CariniiPneumonia
- A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression
- Tamoxifen-induced Radiation Recall Dermatitis
- The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells.
- The treatment of combination chemotherapy‐resistant Hodgkin disease with single‐agent vinblastine
- Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy
- Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer
- Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function
- Evaluation of a virtual dialogue method for breast cancer patient education
- Breaking Down Barriers to Breast and Cervical Cancer Screening: A University-based Prevention Program for Latinas
- Fatal Overdose of Propoxyphene Napsylate and Aspirin
- Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
- Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines
- A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity
- SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.
- HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane